Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • AYUSH
    • Patanjali group eyes...

    Patanjali group eyes to be Rs 40,000-crore company in 2020-21

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-25T12:24:22+05:30  |  Updated On 25 Jan 2020 12:24 PM IST
    Patanjali group eyes to be Rs 40,000-crore company in 2020-21

    New Delhi: Haridwar-based Patanjali group, which has acquired debt-ridden Ruchi Soya, expects to have a turnover of Rs 35,000-Rs 40,000 crore in the next financial year and to become the largest company in the FMCG sector in the coming years replacing market leader HUL, said Yoga Guru Ramdev here on Friday.

    The company is expected to register a joint turnover of up to Rs 25,000 crore in the current financial year, in which around Rs 12,000 crore is likely to be contributed by Patanjali group firms and Rs 13,000 crore may come from Ruchi Soya, he said.

    After the acquisition of Ruchi Soya, Ramdev-promoted Patanjali expects a three-fold growth, become a major player in the edible oil category and take a lead in the domestic production of soyabean oil, sunflower oil and palm oil.

    "This fiscal, Patanjali along with Ruchi Soya would have a turnover of around Rs 25,000 crore and expects to grow up to around Rs 35,000 crore-Rs 40,000 crores by the next fiscal year (FY21)," Ramdev said.

    He further said, "In the next five years, we would have a turnover of around Rs 50,000 crore to Rs 1 lakh crore and will become the largest FMCG company, replacing HUL."

    Hindustan Unilever Ltd (HUL), the market leader in the FMCG segment, had reported a revenue of Rs 38,224 crore in 2018-19 and this is expected to go up with the merger with GSK Healthcare's business.

    When contacted, an HUL spokesperson said, "As a policy, we do not comment on competition."

    Patanjali had acquired Ruchi Soya in a corporate insolvency resolution process for around Rs 4,350 crore after competing with Adani Group.

    In the next two years, 25 per cent shares of Ruchi Soya will have to be liquidated as per the Securities and Exchange Board of India (Sebi) guidelines, said Ramdev.

    The company expects a higher growth coming from Ruchi Soya, where it is aiming multi-fold growth and is introducing new products by extending its existing popular brand Nutrela.

    "We will launch three new products under Nutrela brand targeting the health-conscious people and the people suffering from diseases such as heart ailments, cholesterol and high blood pressure," he said.

    These products are Oil Nutrela Gold, Nutrela Honey and Nutrela Protein Atta.

    "We are expecting three times growth from Ruchi Soya in coming years," Ramdev said adding that it will also lessen the burden of import of edible oil from other countries and make India self-dependent in this sector.

    Both Patanjali and Ruchi Soya would integrate its products by leveraging their strengths and would enhance the respective production capacity and increase market share, he added.

    Patanjali will also continue to have Bollywood actress Madhuri Dixit as the brand ambassador for Ruchi Soya's Mahakosh range of products.

    Moreover, on being asked whether there would be competition between some products of Ruchi Soya and Patanjali Ayurved, Ramdev said the products would not clash and would add value to the customers.

    Read also: Patanjali ties up with Amazon, Flipkart, 1mg, Netmeds, Paytm Mall to push ayurveda products

    "We have a target to expand our reach to 50 crore people in the next five years," he said adding that the Patanjali group is now providing employment opportunities to around two lakh people and a similar number of farmers.

    On being asked about the slowdown in the FMCG segment, Ramdev said it was a temporary phase, and companies selling luxury products were mainly impacted. Companies selling regular household consumption goods such as Patanjali Ayurved and Ruchi Soya were not impacted, he added.

    Read also: Patanjali to set up five institutes in Nagaland

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok